{"Symbol": "ALNY", "AssetType": "Common Stock", "Name": "Alnylam Pharmaceuticals Inc", "Description": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.", "CIK": "1178670", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "675 WEST KENDALL STREET, CAMBRIDGE, MA, UNITED STATES, 02142", "OfficialSite": "https://www.alnylam.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "41696715000", "EBITDA": "557236000", "PERatio": "134.94", "PEGRatio": "-0.49", "BookValue": "5.96", "DividendPerShare": "None", "DividendYield": "None", "EPS": "2.33", "RevenuePerShareTTM": "28.35", "ProfitMargin": "0.0845", "OperatingMarginTTM": "0.12", "ReturnOnAssetsTTM": "0.0681", "ReturnOnEquityTTM": "0.733", "RevenueTTM": "3713937000", "GrossProfitTTM": "3032066000", "DilutedEPSTTM": "2.33", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.849", "AnalystTargetPrice": "459.4", "AnalystRatingStrongBuy": "6", "AnalystRatingBuy": "14", "AnalystRatingHold": "8", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "134.94", "ForwardPE": "41.84", "PriceToSalesRatioTTM": "11.23", "PriceToBookRatio": "52.84", "EVToRevenue": "10.79", "EVToEBITDA": "63.45", "Beta": "0.351", "52WeekHigh": "495.55", "52WeekLow": "205.87", "50DayMovingAverage": "379.4", "200DayMovingAverage": "387.21", "SharesOutstanding": "132623000", "SharesFloat": "132134000", "PercentInsiders": "0.420", "PercentInstitutions": "103.110", "DividendDate": "None", "ExDividendDate": "None"}